Abstract
Corona virus disease 2019 (COVID-19) pandemic has become a globally challenging issue after its emergence in December 2019 from Wuhan, China. Despite its common presentation as respiratory distress, patients with COVID-19 have also shown neurological manifestation especially stroke. Therefore, the authors sought to determine the etiology, underlying risk factors, and outcomes among patients with COVID-19 presenting with stroke. We conducted a systematic review of the electronic database (PubMed, Google Scholar, Scopus, Medline, EMBASE, and Cochrane library) using different MeSH terms from November 2019 to June 2020. A total of 39 patients with stroke from 6 studies were included. The mean age of our included patients was 61.4 ± 14.2 years. Majority of the patients (n = 36, 92.3%) with COVID-19 had ischemic stroke, 5.1% (n = 2) had hemorrhagic stroke, and 2.6% (n = 1) had cerebral venous thrombosis at the time of initial clinical presentation. Almost all of the patients presented had underlying risk factors predisposing to stroke which included diabetes mellitus, hyperlipidemia, hypertension, and previous history of cerebrovascular disease. 51.2% (n = 20) of the included patients infected with COVID-19 with stroke died, while remaining patients were either discharged home or transferred to a rehabilitation unit. Exploring the neurological manifestation in terms of stroke among patients with COVID-19 is a step towards better understanding of the virus, preventing further spread, and treating the patients affected by this pandemic.
Keywords: COVID-19, Corona virus, Pandemic, Stroke, Neurological disorders
Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has emerged as an unprecedented global crisis. In the tremendous flow of viral pneumonia and life-threatening respiratory complications, the influence of corona virus disease 2019 (COVID-19) on neurological diseases remains unclear. Brain is the potential target to COVID-19, just as the lungs, due to expression of angiotensin-converting enzyme (ACE 2) receptors on the glial cells and neurons of the central nervous system [1, 2]. There have been reports on stroke surge, especially among young and middle-age group patients, suffering from COVID-19 [3]. Among patients with COVID-19, serum D-Dimer level is generally increased, which could be the source of embolic vascular event [4]. Study by Klok et al. [5] suggested that the excessive inflammation, hypoxia, immobilization, and diffuse intravascular coagulation predispose to an increased risk of thrombovascular event reaching up as high as 31% among ICU patients with COVID-19. Many of the patients presenting with stroke might already have underlying cerebrovascular risk factors, such as hypertension, hyperlipidemia, diabetes mellitus, smoking, or previous history of stroke [6]. The occurrence of cerebrovascular events in critically ill patients with underlying medical co-morbidities is therefore potentially related to the direct effect of the infection itself or inappropriate host response.
Therefore, we carried out a systematic review of all available literature on patients infected with novel COVID-19 presenting with stroke to determine the overall impact of this pandemic and outcomes among patients having neurological manifestations.
Methods
Data search strategy
We followed the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) [7] guidelines for literature search. Two reviewers (NF and AS) conducted a detailed systematic review on electronic databases using PubMed, Google Scholar, EMBASE, Medline, Cochrane library, and Scopus for articles published between November 1, 2019, and June 1, 2020. MeSH terms (using the Boolean operators “and” and “or”) which included “stroke”, “pandemic”, “corona virus”, and “COVID-19” were searched. All articles irrespective of the language were included in our study.
Inclusion and exclusion criteria
The inclusion criteria included patients presenting with acute stroke who eventually were found to be positive COVID-19. We included all available type of studies on stroke in our review due to scarcity of literature.
Data extraction and outcome measures
The data were extracted by the authors using a structured template form based on the Cochrane Consumers and Communication Group. We further conducted this meta-analysis in accordance with the criteria set by Cochrane Consumers and Communication Group reviews: Meta-analysis [8]. Any disagreement between the two authors was resolved by discussion. The following data were extracted from each article: (i) demographic characteristics, (ii) clinical condition, (iii) stroke risk factors, and (v) outcome measures.
Evidence quality assessment
The Grades of Recommendation, Assessment, Development and Evaluation (GRADE) [9] protocol was used to assess the quality of evidence for each study independently by two reviewers. Each study was rated based on study design, limitations, and results into either high, moderate, low or very low.
Statistical analysis
Rev Manager (Rev Man 5.3) was used for comparing data from the included studies. Pooled weighted mean difference was used to analyze the continuous data, while the odds ratio (OR) was used to analyze the dichotomous data.
Risk of bias across studies
We used the Cochrane Collaboration’s tool to assess the risk of bias across the included studies. Double blindness was not achieved in any study.
Results
Study selection
A total of 98 articles were retrieved from electronic databases (PubMed, Google Scholar, Scopus, Medline, EMBASE, and Cochrane library) and reviewed according to PRISMA guidelines [10] (Fig. 1). After screening of the abstracts, 72 articles were excluded as the data was not related to stroke. A total of 11 full text articles were assessed for eligibility, of which 5 articles were excluded based upon the inclusion and exclusion criterion. Hence, 6 articles were included in our review [3, 11–15]. All included studies were categorized under moderate GRADE.
Study results
Our review included 39 patients presenting with cerebrovascular disease, out of which 36 patients (92.3%) had ischemic stroke, 2 patients (5.1%) had hemorrhagic stroke, and 1 patient (2.6%) had cerebral venous sinus thrombosis. The mean age of our included patients was 61.4 ± 14.2 years. Almost all of the patients had underlying risk factors predisposing to stroke which included diabetes mellitus, hyperlipidemia, hypertension, and previous history of cerebrovascular disease. Outcomes included mortality among 51.2% (n = 20) of the included patients, while remaining patients survived and were transferred either to rehabilitation unit or home. Baseline and outcome characteristics are shown in Table 1.
Table 1.
Name of the author | Year of study | Disease | Mean age (standard deviation), years | Number of patients | Cerebrovascular disorder | Stroke risk factors | Outcome |
---|---|---|---|---|---|---|---|
Mao Ling et al. 2020 [3] | 2020 | COVID-19 | 52.7 (15.5) | 214 |
Ischemic stroke: 5 Cerebral hemorrhage: 1 |
Severe infection, old age, co-morbidities especially hypertension, lower lymphocyte levels, low platelet counts, higher blood urea nitrogen levels | Patients died from respiratory failure |
Oxley T et al. 2020 [11] | 2020 | COVID-19 | 40.4 (5.6) | 5 | Large-vessel ischemic stroke |
Patient 1: none Patient 2: none Patient 3: hyperlipidemia, hypertension Patient 4: undiagnosed diabetes Patient 5: mild stroke, diabetes |
Patient 1: Dx to rehab Patient 2: Dx home Patient 3: ICU Patient 4: stroke unit Patient 5: Dx to rehab |
Li Y et al. 2020 [12] | 2020 | COVID-19 | 71.6 (15.7) | 221 |
Ischemic Stroke: 11 Cerebral Hemorrhage: 1 Cerebral venous sinus thrombosis: 1 |
Hypertension, diabetes, and previous medical history of cerebrovascular disease |
Death: 5 Survived: 8 |
Avula A et al. 2020 [13] | 2020 | COVID-19 | 81 (5.43) | 4 | Ischemic stroke |
Patient 1: hypertension, dyslipidemia and carotid stenosis Patient 2: urinary tract Infection, hypertension, hyperlipidemia, diabetes mellitus and neuropathy Patient 3: hypertension Patient 4: hypertension, chronic kidney disease, hyperlipidemia |
Death: 3 Survived: 1 |
Zhao J et al. 2020 [14] | 2020 | COVID-19 | 60 | 1 | Ischemic stoke | Hypertension | Survived |
Escalard S et al. 2020 [15] | 2020 | COVID-19 | 59.5 | 10 | Ischemic stroke | Hypertension, diabetes mellitus, hypercholesterolemia, smoking, atrial fibrillation, prestroke anticoagulation |
Death: 6 Survived: 4 |
Dx discharge, ICU intensive care unit, NIHSS National Institute of Health Stroke Scale, NA not available
Discussion
Our systematic review determined the underlying risk factors leading to stroke among COVID-19 patients, and outcomes among these patients. Our results suggested that the patients with COVID-19 have an apparent association with stroke due to similar risk factors. There is ample evidence that the severity of COVID-19 infection in humans is directly related to the presence of cardiovascular co-morbidities, which include diabetes mellitus, hypertension, and elderly status predisposing to large and small vessel disease [16, 17]. A recently conducted meta-analysis of 8 studies from China, including 46,248 infected patients, showed that the most prevalent co-morbidities were hypertension (17%) and diabetes mellitus (8%), followed by cardiovascular diseases (5%) [18, 19]. In those reported cases without any vascular factors, the SARS-CoV-2-induced hypercoagulability may be the most important mechanism of the cerebrovascular disease [13, 20].
Previously large-vessel stroke was reported to be associated with SARS CoV-1 outbreak in Singapore [21]. Various hypotheses had been suggested to explain the apparent link between viruses and cerebrovascular diseases, which include, but are not limited to, virus-induced inflammation of the vessel wall [22] and induction of prothrombinase gene [23]. Furthermore, Middle East respiratory syndrome corona virus (MERS-CoV) [24] also led to severe neurological manifestation among patients. In the setting of a COVID-19 infection, patients with previous history of vascular risk factors might have an increased risk of stroke due to complications such as shock, hypotension, heart failure, and disseminated intravascular coagulation that can potentially contribute to hypoperfusion, embolic mechanism of stroke, and large vessel occlusion [11, 16, 17]. In some recent observational studies of hospitalized patients of COVID-19, shock was observed in 8.7–20% of the patients, acute cardiac injury in 7.2–17% of the patients, and coagulopathy in 19% of the patients [25, 26].
Neurosurgeons and neurologists should keep in mind the potential risks of stroke among these presenting patients. There are recommendations [27–29] set up by the treating physicians for the optimal stroke care during this pandemic crisis. We therefore appreciate the efforts by the neurologists and the vascular neurosurgeons to better understand the underlying risk factors and complications in order to improve the overall outcome of the stroke patients in this pandemic crisis. We carried out a short-systematic review integrating all COVID-19 patients presenting with stroke. This would definitely help in understanding the difference in the age groups and outcomes among these patients presenting at various institutes. However, further studies are needed to understand the presence of specific viral factors causing hypercoagulability, arteritis, endothelial dysfunction, and as a result different types of ischemic and hemorrhagic stroke due to COVID-19.
Abbreviations
- SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
- COVID-19
Corona virus disease 2019
- ACE
Angiotensin-converting enzyme
- PRISMA
Preferred Reporting Items for Systematic Review and Meta-analysis
Compliance with ethical standards
Conflict of interest
None
Ethical disclosure
Not Applicable
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Contributor Information
Nida Fatima, Email: nfatima@mgh.harvard.edu.
Maher Saqqur, Email: msaqqur@ualberta.ca.
Fatima Qamar, Email: fqamar1@jhu.edu.
Samia Shaukat, Email: samiashaukat137@gmail.com.
Ashfaq Shuaib, Email: shuaib@ualberta.ca.
References
- 1.Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol. 2008;82:7264–7275. doi: 10.1128/jvi.00737-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, Rusconi S, Gervasoni C, Ridolfo AL, Rizzardini G, Antinori S, Galli M. Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis. 2020;71:889–890. doi: 10.1093/cid/ciaa330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mao L, Wang M, Chen S, He Q, Chang J, Hong C, Zhou Y, Wang D, Miao X, Hu Y, Li Y, Jin H, Hu B (2020) Neurological manifestations of hospitalized patients with COVID-19 in Wuhan, China: a retrospective case series study. SSRN Electron J. 10.2139/ssrn.3544840
- 4.Lau KK, Yu WC, Chu CM, Lau ST, Sheng B, Yuen KY. Possible central nervous system infection by SARS coronavirus. Emerg Infect Dis. 2004;10:342–344. doi: 10.3201/eid1002.030638. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Guan W, Ni Z, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382:1708–1720. doi: 10.1056/nejmoa2002032. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–1012. doi: 10.1016/j.jclinepi.2009.06.005. [DOI] [PubMed] [Google Scholar]
- 8.Ryan R (2013) Cochrane Consumers and Communication Review Group: data synthesis and analysis. Cochrane Consum Commun Rev Gr. http://cccrg.cochrane.org
- 9.Oxman AD. Grading quality of evidence and strength of recommendations. Br Med J. 2004;6:e1000151. doi: 10.1371/journal.pmed.1000151. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Moher D, Liberati A, Tetzlaff J AD. PRISMA 2009 Flow Diagram. Prism statement 2009. 10.1371/journal.pmed1000097
- 11.Oxley Thomas J, Mocco J, Majidi SKC (2009) Large-vessel stroke as a presenting feature of Covid-19 in the young. (Panel D):2008–2009. 10.1056/NEJMc2001272 [DOI] [PMC free article] [PubMed]
- 12.Li Y, Wang M, Zhou Y, Chang J, Xian Y, Mao L, Hong C, Chen S, Wang Y, Wang H, Li M, Jin H, Hu B (2020) Acute cerebrovascular disease following COVID-19: a single center, retrospective, observational study. SSRN Electron J. 10.2139/ssrn.3550025 [DOI] [PMC free article] [PubMed]
- 13.Avula A, Nalleballe K, Narula N, Sapozhnikov S, Dandu V, Toom S, Glaser A, Elsayegh D. COVID-19 presenting as stroke. 2020;(January):19-21. 10.1016/j.bbi.2020.04.077 [DOI] [PMC free article] [PubMed]
- 14.Zhao J, Rudd A, Liu R. Challenges and potential solutions of stroke care during the coronavirus disease 2019 (COVID-19) outbreak. Stroke. 2020;51:1356–1357. doi: 10.1161/STROKEAHA.120.029701. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Escalard S, Maïer B, Redjem H et al (2020) Treatment of acute ischemic stroke due to large vessel occlusion with COVID-19: experience from Paris. Stroke (August):STROKEAHA120030574. 10.1161/STROKEAHA.120.030574 [DOI] [PMC free article] [PubMed]
- 16.Montalvan V, Lee J, Bueso T, De Toledo J, Rivas K. Neurological manifestations of COVID-19 and other coronavirus infections: a systematic review. Clin Neurol Neurosurg. 2020;194:105921. doi: 10.1016/j.clineuro.2020.105921. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Guo J, Huang Z, Lin L, Lv J. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infec. J Am Heart Assoc. 2020;9:e016219. doi: 10.1161/JAHA.120.016219. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, Ji R, Wang H, Wang Y, Zhou Y. Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95. doi: 10.1016/j.ijid.2020.03.017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, Wu Y, Sun L, Xu Y. Prevalence and severity of corona virus disease 2019 (COVID-19): a systematic review and meta-analysis. J Clin Virol. 2020;127:104371. doi: 10.1016/j.jcv.2020.104371. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Panigada M, Bottino N, Tagliabue P et al (2020) Hypercoagulability of COVID-19 patients in intensive care unit. A report of thromboelastography findings and other parameters of hemostasis. J Thromb Haemost. 10.1111/jth.14850 [DOI] [PMC free article] [PubMed]
- 21.Umapathi T, Kor AC, Venketasubramanian N, Lim CCT, Pang BC, Yeo TT, Lee CC, Lim PL, Ponnudurai K, Chuah KL, Tan PH, Tai DYH, Ang SPB. Large artery ischaemic stroke in severe acute respiratory syndrome (SARS) J Neurol. 2004;251:1227–1231. doi: 10.1007/s00415-004-0519-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Doyle PW, Gibson G, Dolman CL. Herpes zoster ophthalmicus with contralateral hemiplegia: Identification of cause. Ann Neurol. 1983;14:84–85. doi: 10.1002/ana.410140115. [DOI] [PubMed] [Google Scholar]
- 23.Key NS, Vercellotti GM, Winkelmann JC, Moldow CF, Goodman JL, Esmon NL, Esmon CT, Jacob HS. Infection of vascular endothelial cells with herpes simplex virus enhances tissue factor activity and reduces thrombomodulin expression. Proc Natl Acad Sci U S A. 1990;87:7095–7099. doi: 10.1073/pnas.87.18.7095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Arabi YM, Harthi A, Hussein J, Bouchama A, Johani S, Hajeer AH, Saeed BT, Wahbi A, Saedy A, AlDabbagh T, Okaili R, Sadat M, Balkhy H. Severe neurologic syndrome associated with Middle East respiratory syndrome corona virus (MERS-CoV) Infection. 2015;43:495–501. doi: 10.1007/s15010-015-0720-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y, Zhao Y, Li Y, Wang X, Peng Z. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;323:1061. doi: 10.1001/jama.2020.1585. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.(2020) Temporary emergency guidance to US stroke centers during the COVID-19 pandemic. Stroke. 10.1161/STROKEAHA.120.030023
- 28.Qureshi AI, Abd-allah F, Alsenani F et al (2020) Management of acute ischemic stroke in patients with COVID-19 infection : report of an international panel. 0(0):1–15. 10.1177/1747493020923234 [DOI] [PubMed]
- 29.Dafer RM, Osteraas ND, MD JB. Acute stroke care in the coronavirus disease 2019 Pandemic. J Stroke Cerebrovasc Dis. 2019;2020:104881. doi: 10.1016/j.jstrokecerebrovasdis.2020.104881. [DOI] [PMC free article] [PubMed] [Google Scholar]